NCT05506540 - A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions

Healthy

Interventions

DRUG

ENN0403 1mg

ENN0403 capsules for oral use

DRUG

ENN0403 4mg

ENN0403 capsules for oral use

DRUG

ENN0403 10mg

ENN0403 capsules for oral use

DRUG

ENN0403 20mg

ENN0403 capsules for oral use

DRUG

ENN0403 30mg

ENN0403 capsules for oral use

DRUG

ENN0403 20mg (Fed)

ENN0403 capsules for oral use

DRUG

ENN0403 6mg QD X 14 Days

ENN0403 capsules for oral use

DRUG

ENN0403 12mg QD X 14 Days

ENN0403 capsules for oral use

DRUG

ENN0403 20mg QD X 14 Days

ENN0403 capsules for oral use

DRUG

Placebo

Placebo capsules for oral use

Trial Locations (1)

CMAX Clinical Research Pty Ltd, Adelaide